|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0013216,
umls-concept:C0045093,
umls-concept:C0205179,
umls-concept:C0205263,
umls-concept:C0205420,
umls-concept:C0796306,
umls-concept:C0817096,
umls-concept:C0920321,
umls-concept:C1517927,
umls-concept:C1522449
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-5-4
|
|
pubmed:abstractText |
To determine the maximum tolerated dose (MTD) of gemcitabine every 2 weeks to a concurrent radiotherapy administered during an aggressive program of sequential and simultaneous radio-/chemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0179-7158
|
|
pubmed:author |
pubmed-author:AsadpourBrankaB,
pubmed-author:BreuerChristianC,
pubmed-author:BuellUlrichU,
pubmed-author:EbleMichael JMJ,
pubmed-author:FischedikKarinK,
pubmed-author:GagelBerndB,
pubmed-author:PinkawaMichaelM,
pubmed-author:PirothMarcM,
pubmed-author:ReinartzPatrickP,
pubmed-author:SchmachtenbergAxelA,
pubmed-author:SkobelEricE,
pubmed-author:StanzelSvenS,
pubmed-author:ZimnyMichaelM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
182
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
263-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16673059-Adenocarcinoma,
pubmed-meshheading:16673059-Adult,
pubmed-meshheading:16673059-Aged,
pubmed-meshheading:16673059-Antimetabolites, Antineoplastic,
pubmed-meshheading:16673059-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:16673059-Carcinoma, Adenosquamous,
pubmed-meshheading:16673059-Carcinoma, Large Cell,
pubmed-meshheading:16673059-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16673059-Carcinoma, Squamous Cell,
pubmed-meshheading:16673059-Combined Modality Therapy,
pubmed-meshheading:16673059-Deoxycytidine,
pubmed-meshheading:16673059-Disease Progression,
pubmed-meshheading:16673059-Female,
pubmed-meshheading:16673059-Humans,
pubmed-meshheading:16673059-Infusions, Intravenous,
pubmed-meshheading:16673059-Lung Neoplasms,
pubmed-meshheading:16673059-Male,
pubmed-meshheading:16673059-Middle Aged,
pubmed-meshheading:16673059-Positron-Emission Tomography,
pubmed-meshheading:16673059-Radiotherapy Dosage,
pubmed-meshheading:16673059-Radiotherapy Planning, Computer-Assisted,
pubmed-meshheading:16673059-Remission Induction,
pubmed-meshheading:16673059-Respiratory Function Tests,
pubmed-meshheading:16673059-Time Factors,
pubmed-meshheading:16673059-Treatment Outcome,
pubmed-meshheading:16673059-Vinblastine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
|
|
pubmed:affiliation |
Department of Radiotherapy, RWTH Aachen University, Germany. BGagel@ukaachen.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
